1

#### ultrasound-guided Endobronchial transbronchial mediastinal 1

#### cryobiopsy: Insights and technical tips from our early experience 2

#### with 30 patients 3

25

4	Chun Ian Soo <sup>1</sup> ¶* , Sze Shyang Kho <sup>2</sup> ¶
5	
6	<sup>1</sup> Division of Respiratory Medicine, Department of Medicine, University Malaya Medical
7	Center, University Malaya, Kuala Lumpur, Malaysia
8	<sup>2</sup> Division of Respiratory Medicine, Department of Medicine, Sarawak General Hospital
9	Kuching, Malaysia
10	
11	Short title: Endobronchial ultrasound guided cryobiopsy
12	
10	
13	
14	
15	
16	
17	
18	
19	
20	*Corresponding Author
21	Name: Chun Ian Soo
22	Email: scianray@gmail.com
23	
24	<sup>¶</sup> These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 26 Abstract

27

# 28 Background

29

30 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is 31 commonly used to diagnose and stage lung cancer. In real-life practice, limitations are 32 seen with cytology samples from EBUS-TBNA. Obtaining adequate samples can be 33 challenging when faced with necrotic lesions with low cellular yield and the evolving 34 landscape of targeted therapy, necessitating additional samples for comprehensive 35 testing. Hence, transbronchial mediastinal cryobiopsy guided by endobronchial 36 ultrasound (EBUS-TBMC) has emerged as a promising approach for obtaining larger 37 tissue samples. In retrospective review, our aim is to present our early experience 38 regarding the feasibility of performing EBUS-TBMC, employing a similar approach to 39 EBUS-TBNA, followed by the outcomes of our procedures. We include a step-by-step 40 explanation and some recommendations to conduct a successful EBUS-TBMC.

41

## 42 Method

43 Single center retrospective analysis to evaluate the feasibility and utility of EBUS44 TBMC cases over six months from July to December 2022.

45

#### 46 **Results**

36 EBUS-TBMC procedures on 30 patients. Moderate sedation was used in 80% of
cases. Majority (83.4%) of the patients had biopsy of a single lesion with a median of
3 cryobiopsies (Interquartile range 3-4). The median cryo-activation time was 6
seconds (Interquartile range 6-8). EBUS-TBMC demonstrated a positive yield of 86.1%

3

with an overall diagnostic yield of 83.3%. Mild bleeding occurred in six biopsies (16.7%)
which did not required further intervention. No other major complications were
observed.

54

## 55 **Conclusion**

56 EBUS-TBMC is a safe and effective alternative to EBUS-TBNA. Histology samples 57 obtained through EBUS-TBMC have the potential to increase confidence in diagnosing 58 and staging lung cancer, thereby alleviating concerns about tissue inadequacy.

59

# 60 **1.Introduction**

61 Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) 62 is a minimally invasive technique commonly employed for diagnosing and staging 63 lung cancer [1-2]. However, diagnostic challenges of EBUS-TBNA are seen when 64 dealing with low-cellularity lesions, particularly those involving necrosis or non-65 malignant conditions [3]. With the emergence of targeted therapy in non-small cell 66 lung carcinoma (NSCLC), additional samples are necessary for immunological 67 profiling and molecular testing. Although transbronchial forceps biopsy and larger 68 cytology needles have been attempted in such cases, their efficacy remains 69 uncertain [3].

A newer technique, transbronchial mediastinal cryobiopsy guided by endobronchial ultrasound (EBUS-TBMC), has recently gained popularity for obtaining larger tissue samples. Despite its growing use, the feasibility, optimal sampling strategy, diagnostic accuracy, and safety profile of EBUS-TBMC are

subjects of ongoing debate. As regular EBUS-endoscopists, we have also explored EBUS-TBMC. In this short commentary, we share our early experience with the feasibility and utility of EBUS-TBMC. In addition, we offer a detailed exposition of the employed technique, with the intent of enriching readers' comprehension and offering invaluable insights into the procedure and its clinical applications.

# 79 **2. Methods**

We conducted a retrospective analysis of EBUS-TBMC cases performed at a single tertiary center between July and December 2022. The clinical data of the patients, including radiological images and EBUS-TBMC findings were traced using the hospital's electronic medical records. The authors had access to participants information during data collection.

85 An experienced operator carried out the EBUS-TBMC procedure using a 1.1-mm 86 flexible cryoprobe (Erbecryo 20402-401, Tubingen, Germany). The procedure was 87 conducted under either moderate sedation or general anesthesia, following 88 established guidelines [4]. The entry point and biopsy track (BT) for the cryoprobe were created using a needle (19, 21, or 22-gauge), followed by an unspecified 89 90 number of cryo-activations per biopsy. The choice of needle size was based on the 91 operator's assessment of the type and location of the lesion, while the number of 92 cryo-activations per biopsy was determined at the operator's discretion. The frozen 93 biopsy tissue was retracted en-bloc with the scope and probe, and the thawed 94 samples were fixed in formalin. Rapid onsite cytology examination was not 95 available during the procedures. For our analysis, we defined a positive yield as a definitive histology diagnosis from each biopsy, while the diagnostic yield was 96 97 based on diagnoses from available histology samples. The study protocol received

approval from the Medical Research and Ethics Committee, Ministry of Health
Malaysia (NMRR ID-23-00577-6XP), and informed consent was waived for this
retrospective study.

# 101 **3.Results**

102 A total of 36 EBUS-TBMC procedures were performed on 30 patients. Moderate 103 sedation was utilized in 80% of cases. On average, 3 EBUS-TBMCs were 104 conducted per patient (interguartile range [IQR]: 3-4), with an activation time of 6 105 seconds (IQR: 6-8). In the majority of cases, EBUS-TBMC was performed on a 106 single lesion, accounting for 83.4% (25 patients) of the total. Among the biopsies conducted, 83.3% (30 biopsies) targeted lymph nodes, while the remaining 16.7% 107 108 (6 biopsies) were performed on masses. Only two instances of failure in cryoprobe 109 insertion were observed.

The median cumulative tissue size retrieved during EBUS-TBMC procedures was 6 mm (IQR: 5-8). Notably, the positive yield of EBUS-TBMC was 86.1% (31 lesions), contributing to an overall diagnostic yield of 83.3% (25 cases). Table 1 presents the baseline characteristics and diagnostic yield. Mild bleeding occurred in six cases (16.7%) but did not require any intervention. Fortunately, no pneumothoraces, pneumomediastinum, mediastinitis, or other complications were observed.

117	Table 1. Baseline characteristics and diagr	nostic yield of EBUS-TBMC
-----	---	---------------------------

Variable	Number (%)	
Number of patients	30	
Number of cryobiopsy	36	
Sex		
Male	19 (63.3)	

1
ь
v

Female	11 (36.7)	
Sedation		
Moderate sedation	24 (80.0)	
General anaesthesia	6 (20.0)	
General anaestnesia	0 (20.0)	
Number of EBUS-TBMC	Total	Fail
attempted/patient		
1	25 (83.4)	2 (6.7)
2	4 (13.3)	0
2 3	1 (3.3)	0
Number of EBUS-TBMC activation,		
2	7 (19.4)	
3	12 (33.3)	
4	11 (30.6)	
5	4 (11.1)	
6	2 (5.6)	
EBUS-TBMC activation time	01 (50 0)	
<7 (4-6 sec)	21 (58.3)	
>7 (8-10 sec)	15 (41.7)	
Type of lesions		
Lymph nodes	30 (83.3)	
Mass	6 (16.7)	
	0 (10.7)	
Lymph nodes (station)		
4R	9 (30.0)	
11/10R	2 (6.7)	
7	16 (53.4)	
11/10L	1 (3.3)	
4L	1 (3.3)	
Others	1 (3.3)	
Mass		
Paratracheal mass	2 (33.3)	
Posterior tracheal lesion	2 (33.3)	
Hilar mass	2 (33.3)	
	2 (33.3)	
Positive yield	31 (86.1)	
Positive diagnosis	25 (83.3)	
Malignancy	15 (50.0)	
Non malignancy	10 (33.3)	
Malignancy		
Adenocarcinoma	11 (73.3)	
Squamous carcinoma	1 (6.7)	
Squarrous varentonia	1 (0.7)	

Small cell carcinoma	3 (20.0)
Non-malignant	
Tuberculosis	2 (20.0)
Sarcoidosis	2 (20.0)
Granulomatous	2 (20.0)
Reactive	4 (40.0)
Note: Values are presented as number (%)	

119 Note: Values are presented as number (%)

- 120 Abbreviation: Transbronchial mediastinal cryobiopsy guided by endobronchial ultrasound= EBUS-
- 121 TBMC
- 122

#### 123 4.Discussion

124 4.1 Technical aspect

125 EBUS-TBMC, akin to EBUS-TBNA, can be carried out with moderate sedation [5-

6]. For enhanced patient tolerance or when dealing with small or multiple lesions, 126

the procedure is preferably performed under deep sedation or general anaesthesia 127

128 [7]. In our study, we primarily conducted EBUS-TBMC under moderate sedation,

129 as regular anaesthesia support was unavailable.

130 When EBUS-TBMC is employed as an ancillary test for EBUS-TBNA, it is 131 advisable to conduct EBUS-TBMC as the initial procedure. This approach allows 132 for the precise identification of a proper and consistent entry point and BT created 133 by repeated punctures of the TBNA needle. In our procedures, we did not use high-134 frequency needle knives, in line with a previous studies [6]. However, using a 135 needle knife may potentially reduce the overall procedural duration [5-6]. Using a 136 21-gauge needle, around 5-6 agitations over the capsule than the cortex, following 137 a similar trajectory visible on ultrasound and bronchoscopic vision, are required to 138 create a BT after puncturing the membranous part of the tracheobronchial wall. 139 The number of agitations may need to be adjusted depending on whether a larger

8

or smaller needle is used. The cryoprobe is then inserted precisely perpendicularto the BT into the lesion.

EBUS-TBMC can be conveniently performed at lymph node stations commonly sampled via EBUS-TBNA. However, our experience reveals that EBUS-TBMC presents challenges for posterior tracheal lesions due to the difficulty of rotating the scope 180 degrees. Nevertheless, we believe that mastering EBUS-TBMC requires a steep learning curve. Fig 1 provides a pictorial narrative of the procedure, and Fig 2 depicts the landmarks corresponding to the complexity level of performing EBUS-TBMC.

149 Figure caption

150 Fig 1:

151 Pictorial narrative of the EBUS-TBMC procedure (In alphabetical sequence)

(A) Biopsy track created by TBNA needle seen on ultrasound (blue arrow), (B and C)
Biopsy track (blue arrow) and TBNA needle (red arrow) seen at the same trajectory
and different depth, (D) Entry point seen after a 22 gauge TBNA needle puncture
(black arrow), (E) Avoiding entry of cryoprobe at obtuse angle, (F) Maintain
perpendicular entry of cryoprobe, (G) Ensure cryoprobe is clearly visible in lesion, (H)
Samples thawed in saline and fixed in formalin, (I) Sample size obtained at different
cryo-activation time.

159

160 Fig 2:

161 Landmarks and the complexity degree of performing EBUS-TBMC

162 Abbreviation: Transbronchial mediastinal cryobiopsy guided by endobronchial ultrasound =EBUS-

163 TBMC, Transbronchial needle aspiration =TBNA

164

# 165 4.2 Diagnostic yield

166 Various studies have demonstrated that incorporating EBUS-TBMC alongside 167 conventional EBUS-TBNA can significantly improve the diagnostic yield, especially 168 for benign disorders, lymphomas, and rare mediastinal conditions [5-6,8-9]. 169 However, it is essential to acknowledge that intra-lesion necrosis or fibrotic lymph 170 nodes may occasionally limit tissue availability, resulting in a potential reduction in 171 diagnostic yield [10]. Another limitation of EBUS-TBMC involves addressing the 172 heterogeneity of lymph nodes, as the procedure may not allow for biopsies at 173 multiple sites, unlike EBUS-TBNA, which can sample a larger area through 174 different needle entry points or the fanning technique [11].

175 Despite this limitation, EBUS-TBMC offers several advantages. Histology samples 176 obtained from EBUS-TBMC enable more comprehensive testing compared to 177 cytology examination, especially when dealing with poorly differentiated tumours. 178 This aspect is particularly crucial for obtaining accurate diagnoses and guiding 179 treatment decisions. One of the most significant clinical implications of EBUS-180 TBMC lies in its ability to provide sufficient tissue for complete molecular profiling before initiating targeted therapy for non-small cell lung carcinoma (NSCLC) [8]. 181 182 Additionally, in cases of multiple synchronous/metachronous lung cancers, large 183 tissue specimens are often required for comprehensive testing, underscoring the 184 indispensability of EBUS-TBMC in such clinical scenarios.

In our study, we achieved an overall diagnostic yield of 83.3% (25 cases) with an
83.3% diagnostic yield for malignancy. All 12 patients diagnosed with NSCLC had

9

adequate samples from EBUS-TBMC for next-generation sequencing testing.
Nonetheless, it is essential to acknowledge that EBUS-TBMC did not establish a
diagnosis in four cases. The contributing factors include poor patient tolerance,
imprecise biopsy location, and extensive necrosis.

191 4.3 Complication

Minor bleeding was observed in six cases, but no intervention was required, indicating a manageable and self-limiting complication. To further mitigate the risk of bleeding, we recommend conducting Doppler assessments for vascular evaluation before the biopsy. This approach helps identify potential vascular structures and allows for safer probe placement during the procedure.

While rare, pneumothorax and pneumomediastinum have been reported in some cases [5]. As a precautionary measure, we routinely perform post-procedure chest radiographs to promptly detect any signs of air leak. Fortunately, no instances of pneumothorax, pneumomediastinum, mediastinitis, or mortality were observed in our cohort, which is consistent with previous studies demonstrating the overall safety of EBUS-TBMC [5-8].

In our study, we did not administer prophylactic antibiotics, even when sampling large necrotic lesions. This decision aligns with current guidelines and is supported by the lack of observed infections or complications related to the absence of antibiotic prophylaxis. Nevertheless, we emphasize the importance of cautious and skilled execution of EBUS-TBMC to minimize the risk of adverse events. While the procedure offers valuable benefits in obtaining larger tissue samples, operators

11

should be well-trained and familiar with the technique's intricacies to ensure patientsafety.

211 4.4 Advantage and disadvantages

212 Despite some studies reporting mixed outcomes regarding procedure time [5-7], 213 our observations suggest that EBUS-TBMC and EBUS-TBNA may have 214 comparable overall procedure times. We have an ongoing study to validate this 215 hypothesis. One significant drawback of EBUS-TBMC is its cost, necessitating 216 careful consideration and justification of its use. The expense of a single-use 217 cryoprobe is more than twice that of a TBNA needle, rendering an EBUS-TBMC 218 procedure to cost almost three times more expensive. However, it is noteworthy 219 that the future development of a cryo-needle may offer a potential solution to 220 address this cost concern [12]. Table 2 provides an overview of the advantages 221 and disadvantages of EBUS-TBMC. Notably, EBUS-TBMC has the potential to be 222 advantageous in cases with low diagnostic yields using EBUS-TBNA, as it may help avoid repeat procedures, ultimately leading to cost savings. Further 223 224 prospective studies are necessary to ascertain its efficacy.

225 226

Table 2. Advantages and disadvantages of EBUS-TBMC and the proposed solution.

Advantages of EBUS-TBMC		
Providing histology sample whereas TBNA p	provides cytology sample.	
Increase diagnostic yield when used alone or malignant lesions <sup>[5-6,8]</sup> .	combined with TBNA for benign and	
Improved sample suitability for full molecular profiling <sup>[6,8]</sup> .		
Larger sample <sup>[5-9]</sup> .		
Less crush artifact compare to forcep biopsy. <sup>[9]</sup>		
Does not require the support of ROSE.		
Can be performed by experience operator under moderate sedation.		
Disadvantages of EBUS-TBMC	Proposed solution	
Challenging for certain landmarks. Refer to	EBUS-TBNA to be used for challenging	
Fig 2.	landmarks.	

Sampling from single area of a lesion.	Deep sedation or general anaesthesia
Not feasible to apply fanning technique.	support for challenging cases (small lesion, multiple lesions or multiple sampling from different area of a lesion).
Not well explored through EUS-B compare to TBNA.	Potentially feasible [13-14]. Further studies are required.
Higher cost of procedure.	EBUS-TBMC can be considered when anticipating lower yield with TBNA or inconclusive when ROSE is available.
Abbreviation: Endobronchial ultrasound-guided tra	nsbronchial needle aspiration = EBUS-TBNA.

227 228

Transbronchial mediastinal cryobiopsy guided by endobronchial ultrasound =EBUS-TBMC, 229 Endoscopic ultrasound using EBUS scope = EUS-B, Rapid on site examination = ROSE

- 230
- 231 4.5 Limitation of current study

232 The current study has several limitations that require consideration. One limitation 233 of the study is the relatively small sample size, and the fact that it was conducted 234 at a single center. As a result, the findings may not be fully generalizable to broader 235 populations or diverse clinical settings. Conducting larger multi-center studies can 236 help validate and enhance the robustness of the results. Another limitation arises 237 from the retrospective nature of the study design, which may introduce potential 238 biases such as selection bias, information bias, and recall bias. The reliance on 239 existing data and historical records may impact the accuracy and completeness of the findings. Despite these limitations, the study provides valuable insights into the 240 241 feasibility and utility of EBUS-TBMC. Recognizing and addressing these limitations 242 in future research endeavours will contribute to a more comprehensive 243 understanding of the clinical implications and benefits of EBUS-TBMC.

#### 5. Conclusion 244

246 In conclusion, our study demonstrates the feasibility and safety of endobronchial 247 ultrasound-guided transbronchial mediastinal cryobiopsy (EBUS-TBMC) through the biopsy track created by a TBNA needle. The procedure, performed under moderate 248 249 sedation, provides a high diagnostic yield, offering valuable insights into mediastinal 250 disorders and lung cancers. The favourable safety profile and larger tissue samples 251 obtained through EBUS-TBMC enhance diagnostic accuracy and molecular testing, 252 potentially optimizing therapeutic decision-making. As evidence continues to emerge, 253 EBUS-TBMC has the potential to transition from an ancillary test to a primary method, 254 complementing or even replacing EBUS-TBNA in certain clinical scenarios. 255 256 In summary, our study contributes valuable insights into the growing evidence on 257 EBUS-TBMC. The procedure's diagnostic capabilities, safety, and ease of 258 implementation underscore its potential significance in diagnosing various mediastinal 259 disorders and lung cancers. As the field advances, EBUS-TBMC holds promise as a 260 key diagnostic modality shaping the future of diagnostic bronchoscopy. 261 Disclosure 262 The authors have no conflict of interest relevant to this article to report 263 264 265 **References:** 266 1. Detterbeck FC, Jantz MA, Wallace M, Vansteenkiste J, Silvestri GA. Invasive 267 268 mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007;132(3):202S-20S 269

270

271	2. Wahidi MM, Herth F, Yasufuku K, Shepherd RW, Yarmus L, Chawla M, et al.
272	Technical aspects of endobronchial ultrasound-guided transbronchial needle
273	aspiration: CHEST guideline and expert panel report. Chest. 2016;149(3):816-35.
274	
275	3. Eapen GA, Shah AM, Lei X, Jimenez CA, Morice RC, Yarmus L, et al.
276	Complications, consequences, and practice patterns of endobronchial ultrasound-
277	guided transbronchial needle aspiration: results of the AQuIRE registry. Chest.
278	2013;143(4):1044-53.
279	
280	4. Du Rand IA, Barber PV, Goldring J, Lewis RA, Mandal S, Munavvar M, et al.
281	British Thoracic Society guideline for advanced diagnostic and therapeutic flexible
282	bronchoscopy in adults. Thorax. 2011; 66(Suppl 3):iii1-21.
283	
284	5. Zhang J, Guo JR, Huang ZS, Fu WL, Wu XL, Wu N, et al. Transbronchial
285	mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial.
286	Eur Respir J. 2021;58(6).
287	
288	6. Ariza-Prota M, Pérez-Pallarés J, Fernández-Fernández A, García-Alfonso L,
289	Cascón JA, Torres-Rivas H, et al. Endobronchial ultrasound-guided transbronchial
290	mediastinal cryobiopsy in the diagnosis of mediastinal lesions: safety, feasibility and
291	diagnostic yield-experience in 50 cases. ERJ Open Res. 2023;9(2).
292	
293	7. Maturu VN, Prasad VP, Vaddepally CR, Dommata RR, Sethi S. Endobronchial
294	Ultrasound-guided Mediastinal Lymph Nodal Cryobiopsy in Patients With

295	Nondiagnostic/Inadequate Rapid On-site Evaluation: A New Step in the Diagnostic
296	Algorithm. J Bronchology Interv Pulmonol. 2023:10-97
297	
298	8. Fan Y, Zhang AM, Wu XL, Huang ZS, Kontogianni K, Sun K, et al. Transbronchial
299	needle aspiration combined with cryobiopsy in the diagnosis of mediastinal diseases:
300	a multicentre, open-label, randomised trial. Lancet Respir Med. 2023;11(3):256-64.
301	
302	9. Kho SS, Soo CI, Nasaruddin MZ, Ngan KW, Abdul Rahaman JA. Multimodal
303	linear endobronchial ultrasound guided mediastinal lymph node biopsy in the
304	diagnosis of isolated mediastinal lymphadenopathy. Proc Singapore Healthc.
305	2022;31:20101058221111655.
306	
307	10. Tian Q, Chen LA, Wang RT, Yang Z, An Y. The reasons of false negative results
308	of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis
309	of intrapulmonary and mediastinal malignancy. Thoracic Cancer. 2013;4(2):186-90.
310	
311	11. Parthiban S, Sczaniecka A, Dillard D, Gonzalez X. Comparison of Fanning and
312	No-Fanning Sampling Techniques for Endobronchial Ultrasound-Guided
313	Transbronchial Needle Aspiration in an Ex Vivo Tissue Model. Chest.
314	2017;152(4):A964.
315	
316	12. Franke KJ, Nilius G, Ruehle KH, Enderle MD, Linzenbold W, von Weyhern CH.
317	The cryo-needle: a new tool for histological biopsies. A feasibility study. Lung.
318	2013;191:611-7
319	

- 320 13. Huang ZS, Zhou D, Zhang J, Fu WL, Wang J, Wu XL, et al. Mediastinal nodular
- 321 lymphocyte predominant Hodgkin lymphoma achieved by endoscopic
- transesophageal cryobiopsy. Respiration. 2022;101(2):190-4.
- 323 14. Ariza-Prota MA, de Santis M, López-González F. Successful Diagnostic
- 324 Mediastinal Cryobiopsy by Transesophageal Endoscopy Without Using the Needle
- 325 Knife. Arch. Bronconeumo. 2023 Jul 10.





Figure 1



Landmarks and complexity degree for EBUS-TMC

Interlobar and subcarinal: Low

Upper and lower paratracheal: Reasonable

Hilar: Can be challenging

Posterior tracheal: Challenging

# Figure 2